Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues

Curr Treat Options Oncol. 2022 Dec;23(12):1645-1663. doi: 10.1007/s11864-022-01026-3. Epub 2022 Oct 21.

Abstract

Primary neuroendocrine tumors (NETs) of the lung represent a heterogeneous group of malignancies arising from the endocrine cells, involving different entities, from well differentiated to highly undifferentiated neoplasms. Because of the predominance of poorly differentiated tumors, advanced disease is observed at diagnosis in more than one third of patients making chemo- or chemoradiotherapy the only possible treatment. Complete surgical resection, as defined as anatomical resection plus systematic lymphadenectomy, becomes a reliable curative option only for that little percentage of patients presenting with stage I (N0) high-grade NETs. On the other hand, complete surgical resection is considered the mainstay treatment for localized low- and intermediate-grade NETs. Therefore, in the era of the mini-invasive surgery, their indolent behavior has suggested that parenchyma-sparing resections could be as adequate as the anatomical ones in terms of oncological outcomes, leading to discuss about the correct extent of resection and about the role of lymphadenectomy when dealing with highly differentiated NETs.

Keywords: Carcinoids; Multidisciplinary treatment; Neuroendocrine tumors; SCLC; Surgery.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Neuroendocrine*
  • Humans
  • Lung / pathology
  • Lung Neoplasms* / pathology
  • Neuroendocrine Tumors* / diagnosis
  • Neuroendocrine Tumors* / pathology
  • Neuroendocrine Tumors* / surgery